January 7, 2005 -- Once again—the fourth time in five outings this week—stocks sank in the afternoon, taking biotech shares along for the ride. The Centient Biotech 200™ lost 1.17 points to 3463.57, a comparatively small .03% drop. We discuss American Pharma, awaiting an imminent FDA decision, Sonus, which is signalling it also might have news soon, Keryx, with a drug moving into Phase III, and ID Biomedical, which hopes to crack the US flu vaccine market. In other stories, we debunk a “new” heart disease cause and look at Schering’s Bonefos disappointment.
